Patents by Inventor Andrew D. Simmons

Andrew D. Simmons has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR IDENTIFYING LUNG CANCER OR A HUMORAL IMMUNE RESPONSE AGAINST LUNG CANCER
    Publication number: 20110038801
    Abstract: Methods and compositions are provided for identifying lung cancer or a humoral immune response against lung cancer. Also disclosed are methods for determining whether a subject is responding or is likely to respond to lung cancer immunotherapy.
    Type: Application
    Filed: December 19, 2008
    Publication date: February 17, 2011
    Applicant: BioSante Pharmaceuticals, Inc.
    Inventors: Karin Jooss, Andrew D. Simmons
  • Lentiviral vectors featuring liver specific transcriptional enhancer and methods of using same
    Patent number: 7745179
    Abstract: Recombinant lentiviruses and transfer vectors for transgene delivery as well as methods for gene therapy using such vectors are disclosed. The invention provides a third generation lentiviral packaging system and a set of vectors for producing recombinant lentiviruses, as well as novel tissue specific enhancer and promoter elements useful for optimizing liver specific transgene delivery. The transgene is preferably a blood clotting factor such as human factor IX (hFIX) or human factor VIII (hFVIII) and can be used for treatment of hemophilia.
    Type: Grant
    Filed: January 23, 2007
    Date of Patent: June 29, 2010
    Assignee: GBP IP, LLC
    Inventors: James G. McArthur, Dale J. Talbot, Andrew D. Simmons, Ryan McGuinness, Michael Kelly, Lisa V. Tsui, Thomas Dull
  • Liver specific transcriptional enhancer
    Patent number: 7179903
    Abstract: Recombinant lentiviruses and transfer vectors for transgene delivery as well as methods for gene therapy using such vectors are disclosed. The invention provides a third generation lentiviral packaging system and a set of vectors for producing recombinant lentiviruses, as well as novel tissue specific enhancer and promoter elements useful for optimizing liver specific transgene delivery. The transgene is preferably a blood clotting factor such as human factor IX (hFIX) or human factor VIII (hFVIII) and can be used for treatment of hemophilia.
    Type: Grant
    Filed: July 6, 2004
    Date of Patent: February 20, 2007
    Assignee: Cell Genesys, Inc
    Inventors: James G. McArthur, Dale John Talbot, Andrew D. Simmons, Ryan McGuinness, Michael Kelly, Lisa V. Tsui, Thomas Dull
  • Liver specific transcriptional enhancer
    Publication number: 20040259208
    Abstract: Recombinant lentiviruses and transfer vectors for transgene delivery as well as methods for gene therapy using such vectors are disclosed. The invention provides a third generation lentiviral packaging system and a set of vectors for producing recombinant lentiviruses, as well as novel tissue specific enhancer and promoter elements useful for optimizing liver specific transgene delivery. The transgene is preferably a blood clotting factor such as human factor IX (hFIX) or human factor VIII (hFVIII) and can be used for treatment of hemophilia.
    Type: Application
    Filed: July 6, 2004
    Publication date: December 23, 2004
    Inventors: James G. McArthur, Dale John Talbot, Andrew D. Simmons, Ryan McGuinness, Michael Kelly, Lisa V. Tsui, Thomas Dull
  • Lentiviral vectors encoding clotting factors for gene therapy
    Patent number: 6808905
    Abstract: Recombinant lentiviruses and transfer vectors for transgene delivery as well as methods for gene therapy using such vectors are disclosed. The invention provides a third generation lentiviral packaging system and a set of vectors for producing recombinant lentiviruses, as well as novel tissue specific enhancer and promoter elements useful for optimizing liver specific transgene delivery. The transgene is preferably a blood clotting factor such as human factor IX (hFIX) or human factor VIII (hFVIII) and can be used for treatment of hemophilia.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: October 26, 2004
    Assignee: Cell Genesys, Inc.
    Inventors: James G. McArthur, Dale John Talbot, Andrew D. Simmons, Ryan McGuinness, Michael Kelly, Lisa V. Tsui, Thomas Dull
  • Lentiviral vectors encoding clotting factors for gene therapy
    Publication number: 20030077812
    Abstract: Recombinant lentiviruses and transfer vectors for transgene delivery as well as methods for gene therapy using such vectors are disclosed. The invention provides a third generation lentiviral packaging system and a set of vectors for producing recombinant lentiviruses, as well as novel tissue specific enhancer and promoter elements useful for optimizing liver specific transgene delivery. The transgene is preferably a blood clotting factor such as human factor IX (hFIX) or human factor VIII (hFVIII) and can be used for treatment of hemophilia.
    Type: Application
    Filed: May 14, 2002
    Publication date: April 24, 2003
    Inventors: James G. McArthur, Dale John Talbot, Andrew D. Simmons, Ryan McGuinness, Michael Kelly, Lisa V. Tsui, Thomas Dull